The team's new study builds on those findings and sheds light on the mechanism by which increased magnesium levels may act to protect the brain from neurodegeneration. To explore the protective mechanism, they investigated major signaling pathways critical for synapse function and memory formation. They found that elevated ABeta leads to widespread activation of calcium-dependent signaling molecules that contribute to neuronal degeneration. The activation of these molecules dampens the activity of proteins that are critical for synapse remodeling and memory function – effects that the researchers discovered can be overcome with Magtein therapy.
Magceutics plans to launch a clinical trial in conjunction with Stanford University later this year to determine whether Magtein can reverse memory decline for human patients with Alzheimer's Disease.
Source: "Elevation of Brain Magnesium Prevents and Reverses Cognitive Deficits and Synaptic Loss in Alzheimer's Disease Mouse Model" Wei Li , Jia Yu , Yong Liu , Xiaojie Huang , Nashat Abumaria, Ying Zhu , Xian Huang, Wenxiang Xiong , Chi Ren , Xian-Guo Liu, Dehua Chui , and Guosong Liu in Journal of Neuroscience, 33(19), 8423-8441, published May 8, 2013.
Funding: This work was supported by grants from the National Basic Research Program of China and the National Natural Science Foundation of China. Magtein is patented compound owned by Magceutics, Inc (www.magceutics.com).
|SOURCE Magceutics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved